Page 105 - 2021_06-Haematologica-web

Improved outcomes for non-myeloablative allo-HCT
trial. Lancet Haematol. 2019;6(8):e409-
e418.
9.Gafter-Gvili A, Fraser A, Paul M, van de
Wetering M, Kremer L, Leibovici L. Antibiotic prophylaxis for bacterial infec- tions in afebrile neutropenic patients fol- lowing chemotherapy. Cochrane Database Syst Rev. 2005(4):CD004386.
10.Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infec- tions in afebrile neutropenic patients fol- lowing chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.
11. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malig- nancies. Clin Infect Dis. 2005;40(8):1087- 1093.
12. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoi- etic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25(34):5471-5489.
13. Ethier MC, Science M, Beyene J, Briel M, Lehrnbecher T, Sung L. Mould-active com- pared with fluconazole prophylaxis to pre- vent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. Br J Cancer. 2012;106(10):1626-1637.
14.Peggs KS, Preiser W, Kottaridis PD, et al. Extended routine polymerase chain reac- tion surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogene- ic transplantation. Br J Haematol. 2000;111(3):782-790.
15. Mori T, Okamoto S, Watanabe R, et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(9):777- 782.
16. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99(4):1159-1164.
17.Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
18. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
19. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
20. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant dis- eases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007;110(7):2744- 2748.
21. Hingorani SR, Guthrie K, Batchelder A, et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int. 2005;67(1):272- 277.
22.Boeckh M, Huang M, Ferrenberg J, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real- time PCR. J Clin Microbiol. 2004; 42(3):1142-1148.
23. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094-1097.
24. Chien JW, Boeckh MJ, Hansen JA, Clark JG. Lipopolysaccharide binding protein pro- moter variants influence the risk for gram- negative bacteremia and mortality after allogeneic hematopoietic cell transplanta- tion. Blood. 2008;111(4):2462-2469.
25.De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal dis- ease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-1821.
26. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new represen- tations of old estimators. Stat Med. 1999;18(6):695-706.
27. Storer BE, Gooley TA, Jones MP. Adjusted estimates for time-to-event endpoints. Lifetime Data Anal. 2008;14(4):484-495.
28.LjungmanP,AschanJ,Lewensohn-FuchsI, et al. Results of different strategies for reducing cytomegalovirus-associated mor- tality in allogeneic stem cell transplant recipients. Transplantation. 1998; 66(10):1330-1334.
29.Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell trans- plantation followed by allogeneic or autol- ogous haemopoietic stem-cell transplanta- tion in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12 (13):1195-1203.
30. Gyurkocza B, Storb R, Chauncey TR, Maloney DG, Storer BE, Sandmaier BM. Second allogeneic hematopoietic cell transplantation for relapse after first allo- grafts. Leuk Lymphoma. 2019;60(7):1758- 1766.
44(1):51-56.
34.Monaco F, Scott BL, Chauncey TR, et al.
Total body irradiation dose escalation decrases risk of progression and graft rejec- tion after hematopoietic cell transplanta- tion for myelodysplastic syndromes or myeloproliferative neoplasms. Haematologica. 2019;104(6):1221-1229.
35.Canaani J, Beohou E, Labopin M, et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. J Intern Med. 2019;285(4):407-418.
36.Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res. 2007;31(2):257-259.
37. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allo- geneic HSCT: results of the RELAZA trial. Leukemia. 2012;26(3):381-389.
38.Ryan CE, Sahaf B, Logan AC, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016;128(25):2899-2908.
39. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-731.
40. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myel- ogenous leukemia. Cancer Discov. 2016; 6(10):1106-1117.
41.Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143-153.
42. Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell trans- plant: high response rate but frequent GVHD. Blood. 2017;130(2):221-228.
43. Metzelder SK, Schroeder T, Finck A, et al. High activity of sorafenib in FLT3-ITD-pos- itive acute myeloid leukemia synergizes with allo-immune effects to induce sus- tained responses. Leukemia. 2012;26(11): 2353-2359.
44.Ueda M, de Lima M, Caimi P, et al. Concurrent blinatumomab and donor lym- phocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoi- etic cell transplant. Bone Marrow Transplant. 2016;51(9):1253-1255.
45. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753.
46. Hahn T, McCarthy PL, Jr., Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell trans- plantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013; 31(19):2437-2449.
47. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091-2101.
31.
32.
33.
Greenberg PL, Tuechier H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
Koreth J, Pidaia J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplas- tic syndrome: an international collaborative decision analysis. J Clin Oncol. 2013;31 (21):2662-2670.
Dignan FL, Evans SO, Ethell ME, et al. An early CT-diagnosis-based treatment strate- gy for invasive fungal infection in allogene- ic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant. 2009;
haematologica | 2021; 106(6)
1607